See more : Kikusui Holdings Corporation (6912.T) Income Statement Analysis – Financial Results
Complete financial analysis of Telix Pharmaceuticals Limited (TLPPF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Telix Pharmaceuticals Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- Aclaris Therapeutics, Inc. (ACRS) Income Statement Analysis – Financial Results
- Prestige Consumer Healthcare Inc. (PBH) Income Statement Analysis – Financial Results
- MEHTA SECURITIES LTD. (MEHSECU.BO) Income Statement Analysis – Financial Results
- Xcelerate Inc. (XCRT) Income Statement Analysis – Financial Results
- Bocana Resources Corp. (VC1.F) Income Statement Analysis – Financial Results
Telix Pharmaceuticals Limited (TLPPF)
About Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; scientific and clinical research collaboration with Mauna Kea Technologies; and strategic collaboration agreement with Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 496.66M | 160.10M | 7.60M | 5.21M | 3.49M | 195.14K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 188.16M | 130.76M | 37.36M | 22.09M | 15.36M | 0.00 | 3.79K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 308.50M | 29.34M | -29.77M | -16.88M | -11.88M | 195.14K | -3.79K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 62.12% | 18.32% | -391.85% | -323.75% | -340.75% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 128.84M | 57.86M | 34.14M | 23.09M | 21.16M | 18.69M | 2.98M | 10.00K | 62.00K | 0.00 | 0.00 |
| General & Administrative | 78.99M | 77.32M | 34.92M | 7.71M | 6.51M | 8.50M | 2.46M | 20.00K | 54.00K | 0.00 | 0.00 |
| Selling & Marketing | 54.87M | 16.19M | 5.89M | 1.20M | 312.00K | 577.95K | 213.77K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 133.85M | 44.66M | 17.35M | 9.29M | 7.22M | 9.08M | 2.67M | 20.00K | 54.00K | 0.00 | 0.00 |
| Other Expenses | 0.00 | 3.09M | 23.55M | 2.96M | 11.44M | 11.63M | 112.64K | 0.00 | 0.00 | -994.00K | -578.00K |
| Operating Expenses | 308.50M | 102.52M | 51.48M | 32.38M | 28.38M | 27.85M | 6.52M | 30.00K | 116.00K | -994.00K | -578.00K |
| Cost & Expenses | 451.03M | 233.28M | 88.84M | 54.47M | 43.74M | 27.85M | 6.52M | 30.00K | 116.00K | -994.00K | -578.00K |
| Interest Income | 235.00K | 1.00K | 163.00K | 67.00K | 98.00K | 332.75K | 38.98K | 14.00K | 16.00K | 0.00 | 0.00 |
| Interest Expense | 13.14M | 406.00K | 189.00K | 1.18M | 2.41M | 29.02K | 9.40K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 6.74M | 5.38M | 5.17M | 4.88M | 4.24M | 6.93K | 3.79K | 30.00K | 116.00K | 0.00 | 0.00 |
| EBITDA | 22.97M | -92.84M | -70.07M | -44.94M | -36.17M | -25.82M | -6.77M | -14.00K | -16.00K | -994.00K | -578.00K |
| EBITDA Ratio | 4.62% | -42.35% | -1,001.49% | -851.16% | -1,033.57% | -8,034.10% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 51.89M | -73.18M | -81.25M | -49.25M | -40.26M | -15.68M | -6.37M | -30.00K | -116.00K | -994.00K | -578.00K |
| Operating Income Ratio | 10.45% | -45.71% | -1,069.60% | -944.81% | -1,155.12% | -8,037.67% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -48.80M | -24.52M | -17.79M | -11.00M | 9.13M | 11.94M | 142.22K | -14.00K | -16.00K | 0.00 | 0.00 |
| Income Before Tax | 3.09M | -98.62M | -99.04M | -60.25M | -42.82M | -15.71M | -6.38M | -44.00K | -132.00K | -497.00K | -289.00K |
| Income Before Tax Ratio | 0.62% | -61.60% | -1,303.83% | -1,155.82% | -1,228.55% | -8,052.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -2.12M | 5.46M | -18.53M | -15.37M | -14.95M | -1.88M | 9.40K | -14.00K | -16.00K | -497.00K | -289.00K |
| Net Income | 5.21M | -104.08M | -80.51M | -44.89M | -27.87M | -13.83M | -6.38M | -44.00K | -132.00K | -497.00K | -289.00K |
| Net Income Ratio | 1.05% | -65.01% | -1,059.90% | -861.06% | -799.63% | -7,087.06% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.02 | -0.34 | -0.29 | -0.17 | -0.12 | -0.07 | -0.05 | 0.00 | 0.00 | -0.01 | -0.01 |
| EPS Diluted | 0.02 | -0.34 | -0.29 | -0.17 | -0.12 | -0.07 | -0.05 | 0.00 | 0.00 | -0.01 | -0.01 |
| Weighted Avg Shares Out | 323.66M | 310.64M | 282.21M | 257.27M | 233.44M | 202.12M | 127.99M | 0.00 | 0.00 | 38.67M | 38.67M |
| Weighted Avg Shares Out (Dil) | 323.71M | 310.64M | 282.21M | 257.27M | 233.44M | 202.12M | 127.99M | 0.00 | 0.00 | 38.67M | 38.67M |
Telix to Add FAP-Targeting Candidates to Theranostic Pipeline
Telix ADSs Commence Trading on Nasdaq
Telix Welcomes CMS Decision to Improve Payments for Diagnostic Radiopharmaceuticals
Telix Pharmaceuticals: Strong Momentum Presents Opportunity
Telix Partners with Subtle Medical on AI-Enabled SubtlePET™ Software for Faster PET Imaging with Illuccix®
Telix Spins Off Rhine Pharma™ to Expand Global Access to Radiopharmaceuticals
Telix Files Form 20-F Registration Statement for Nasdaq ADS
Telix Q3 2024 Business Update – Quarterly Revenue Exceeds AU$200M
Health Canada Approves Label Expansion for Telix's Illuccix® to Include Patient Selection for PSMA-Targeted Therapy
Telix to Acquire RLS to Expand North American Manufacturing and Distribution Platform
Source: https://incomestatements.info
Category: Stock Reports